Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
76
CAPR Quote, Financials, Valuation and Earnings
Last price:
$29.67
Seasonality move
:
36.04%
Day range:
$28.51 - $30.17
52-week range:
$4.30 - $40.37
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
121.00x
P/B ratio:
16.17x
Volume:
998.8K
Avg. volume:
4.3M
1-year change:
111.85%
Market cap:
$1.4B
Revenue:
$22.3M
EPS (TTM):
-$1.80
Analysts' Opinion
-
Consensus RatingCapricor Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $50.80, Capricor Therapeutics, Inc. has an estimated upside of 75.78% from its current price of $29.68.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $41.00 representing 100% downside risk from its current price of $29.68.
Fair Value
-
According to the consensus of 8 analysts, Capricor Therapeutics, Inc. has 75.78% upside to fair value with a price target of $50.80 per share.
CAPR vs. S&P 500
-
Over the past 5 trading days, Capricor Therapeutics, Inc. has overperformed the S&P 500 by 9.51% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Capricor Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Capricor Therapeutics, Inc. revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Capricor Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Capricor Therapeutics, Inc. earnings have been falling on a year-over-year basis for 7 quarters in a row. In the most recent quarter Capricor Therapeutics, Inc. reported earnings per share of -$0.54.
Enterprise value:
1.2B
EV / Invested capital:
12.19x
Price / LTM sales:
121.00x
EV / EBIT:
--
EV / Revenue:
111.46x
PEG ratio (5yr expected):
-0.24x
EV / Free cash flow:
-18.14x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$9.4M
Return On Assets:
-60.54%
Net Income Margin (TTM):
-736.62%
Return On Equity:
-77.32%
Return On Invested Capital:
-72.3%
Operating Margin:
-69.16%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $14M | $23.2M | $11.1M | $2.3M | -- | |
| Gross Profit | $13.1M | $21.9M | $9.4M | $1.9M | -$494.7K | |
| Operating Income | -$30.9M | -$35.9M | -$86.7M | -$13M | -$26.3M | |
| EBITDA | -$29.9M | -$34.6M | -$84.9M | -$12.6M | -$25.8M | |
| Diluted EPS | -$1.15 | -$1.06 | -$1.80 | -$0.38 | -$0.54 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $41.3M | $47.5M | $29.5M | $85.8M | $101M | |
| Total Assets | $43.1M | $53.9M | $37.2M | $93M | $126.4M | |
| Current Liabilities | $3M | $23.2M | $32.9M | $20.5M | $28.1M | |
| Total Liabilities | $6.4M | $38.5M | $38.9M | $24.7M | $42.6M | |
| Total Equity | $36.7M | $15.4M | -$1.8M | $68.3M | $83.9M | |
| Total Debt | $3.4M | $5.5M | $5.1M | $4.2M | $17.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$20.9M | -$36.8M | -$61M | -$11.6M | -$19.7M | |
| Cash From Investing | $16.1M | $1.3M | -$69M | $2M | $16M | |
| Cash From Financing | $5.4M | $94.9M | $81.2M | $67.3M | $7K | |
| Free Cash Flow | -$23.4M | -$38.3M | -$68.4M | -$11.7M | -$23.7M | |
CAPR
Sector
Market Cap
$1.4B
$28M
Price % of 52-Week High
73.5%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
-25.4%
-1.54%
1-Year Price Total Return
104.53%
-17.48%
Beta (5-Year)
0.614
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$27.24
200-day SMA
Buy
Level
$10.02
Bollinger Bands (100)
Buy
Level
2.23 - 17.25
Chaikin Money Flow
Sell
Level
-32M
20-day SMA
Buy
Level
$22.01
Relative Strength Index (RSI14)
Buy
Level
73.88
ADX Line
Buy
Level
62.64
Williams %R
Neutral
Level
-30.2741
50-day SMA
Buy
Level
$12.44
MACD (12, 26)
Buy
Level
5.22
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Neutral
Level
60.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (13.7532)
Sell
CA Score
(Annual)
Level (-0.993)
Buy
Beneish M-Score
(Annual)
Level (-2.5902)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (1.5267)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, CAPR has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CAPR average analyst price target in the past 3 months is $50.80.
-
Where Will Capricor Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Capricor Therapeutics, Inc. share price will rise to $50.80 per share over the next 12 months.
-
What Do Analysts Say About Capricor Therapeutics, Inc.?
Analysts are divided on their view about Capricor Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Capricor Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $41.00.
-
What Is Capricor Therapeutics, Inc.'s Price Target?
The price target for Capricor Therapeutics, Inc. over the next 1-year time period is forecast to be $50.80 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CAPR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Capricor Therapeutics, Inc. is a Buy. 8 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CAPR?
You can purchase shares of Capricor Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Capricor Therapeutics, Inc. shares.
-
What Is The Capricor Therapeutics, Inc. Share Price Today?
Capricor Therapeutics, Inc. was last trading at $29.67 per share. This represents the most recent stock quote for Capricor Therapeutics, Inc.. Yesterday, Capricor Therapeutics, Inc. closed at $29.68 per share.
-
How To Buy Capricor Therapeutics, Inc. Stock Online?
In order to purchase Capricor Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CAPR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CAPR
Sector
P/E ratio
--
23.89x
PEG ratio
-0.24x
-0.01x
P/B ratio
16.17x
1.82x
Price / LTM sales
121.00x
1.60x
Growth Metrics
CAPR
Sector
Revenue growth
-100%
4.62%
Earnings growth
-41.63%
10.88%
Revenue (5-year growth)
85.83%
6.5%
Earnings forecast
-$0.54
-$0.21
Profitability
CAPR
Sector
Profitability FY 2024
$20.8M
$3.5M
Return on invested capital
-72.3%
-31.77%
Return on assets
-60.54%
-27.96%
Return on equity
-77.32%
-37.63%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Mar
19
Estimated Next Earnings Date
Feb
9
Balance Sheet
CAPR
Sector
Total cash
$98.6M
$26.3M
Short term investments
$140.2M
$25.7M
Total assets
$170.5M
$78M
Long term debt
$17.8M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
